Plasma p-tau181 has shown predictive value for AD progression up to eight years before clinical diagnosis, and when combined with other biomarkers such as neurofilament light chain (NfL) and Aβ42, it improves predictive accuracy for clinical onset of AD [48]. This evidence concerns the gene NEFL and Alzheimer disease.